Evidence map›Paper›PMID 40077449›Full record

ReviewFoods (Basel, Switzerland)2025

Green Tea: Current Knowledge and Issues.

Maya Radeva-Ilieva, Stanila Stoeva, Nadezhda Hvarchanova, Kaloyan D Georgiev

Abstract readReview
In one paragraph

Review in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Evolutionary and pan-genomic analysis of theFrontiers in plant science · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maya Radeva-IlievaDepartment of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University-Varna, 9002 Varna, Bulgaria.ORCID 0000-0001-5778-4043
Stanila StoevaDepartment of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University-Varna, 9002 Varna, Bulgaria.ORCID 0000-0002-0528-0289
Nadezhda HvarchanovaDepartment of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University-Varna, 9002 Varna, Bulgaria.ORCID 0000-0002-8760-8654
Kaloyan D GeorgievDepartment of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University-Varna, 9002 Varna, Bulgaria.ORCID 0000-0003-1839-1452

Funding

European Union - NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria project № BG-RRP-2.004-0009-C02
6 · The paper itself

Abstract

Green tea possesses antioxidant, anti-inflammatory, anticancer, and antimicrobial activities, reduces body weight, and slows down aging. These effects are primarily attributed to catechins contained in green tea leaves, particularly epigallocatechin-3-gallate. However, in humans, the realization of green tea's beneficial effects is limited. In order to summarize and critically analyze the available scientific information about green tea's health benefits and issues related to its use, we conducted an in-depth literature review in scientific databases. A number of in vitro studies reported that green tea catechins modulate various signaling pathways in cells, which is thought to underlie their beneficial effects. However, data on the effects of catechins in humans are scarce, which is partly due to their low stability and oral bioavailability. Furthermore, catechins may also participate in pharmacokinetic interactions when co-administered with certain drugs such as anticancer agents, drugs for cardiovascular diseases, immunosuppressors, etc. As a result, adverse drug reactions or therapy failure may occur. In conclusion, over the years, various approaches have been investigated to optimize catechin intake and to achieve beneficial effects in humans, but to date, the use of catechins for prophylaxis or disease treatment remains limited. Therefore, future studies regarding the possibilities of catechins administration are needed.

Indexed as

bioavailabilitycatechinsepigallocatechin-3-gallategreen teainteractionpharmacokinetic

Identifiers

PMID40077449
PMCPMC11899301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.